Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Other Non Operating Income (2021 - 2025)

Historic Other Non Operating Income for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $765881.0.

  • SAB Biotherapeutics' Other Non Operating Income rose 148.86% to $765881.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 2725.99%. This contributed to the annual value of $2.5 million for FY2024, which is 46370.19% up from last year.
  • Per SAB Biotherapeutics' latest filing, its Other Non Operating Income stood at $765881.0 for Q3 2025, which was up 148.86% from $295630.0 recorded in Q2 2025.
  • SAB Biotherapeutics' Other Non Operating Income's 5-year high stood at $7.8 million during Q1 2022, with a 5-year trough of -$69138.0 in Q2 2021.
  • Over the past 5 years, SAB Biotherapeutics' median Other Non Operating Income value was $421481.0 (recorded in 2024), while the average stood at $911884.2.
  • As far as peak fluctuations go, SAB Biotherapeutics' Other Non Operating Income tumbled by 6137.11% in 2022, and later surged by 626430.91% in 2023.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Other Non Operating Income stood at $3953.0 in 2021, then surged by 715.25% to $32227.0 in 2022, then soared by 948.52% to $337906.0 in 2023, then skyrocketed by 153.03% to $854997.0 in 2024, then fell by 10.42% to $765881.0 in 2025.
  • Its Other Non Operating Income stands at $765881.0 for Q3 2025, versus $295630.0 for Q2 2025 and $546627.0 for Q1 2025.